Etomerzol for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Etomerzol for Health & Longevity

Created on 10/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Etomerzol, an unapproved synthetic research chemical related to the Soviet performance drug bemitil, was designed to keep people functioning under oxygen shortage, heavy exertion and poisoning. Its best-supported benefit, faster recovery after pesticide poisoning, comes from one small study and does not bear on healthy aging. Endurance gains rest on one loosely controlled study. Injection-site tissue injury is the clearest recorded harm; no long-term safety or longevity evidence exists. (Full Review)

Protocol

No established longevity protocol
None for health or longevity
Every regimen comes from Soviet and Russian military-clinical research
Clinical research regimen (Military Medical Academy, St. Petersburg)
80 mg intramuscularly, once or twice daily
2 mL of a 4% solution for 7–10 days, starting on day 1–2 of poisoning
Oral route (animal-derived alternative, Plotnikov's Tomsk group)
No human oral dose has been tested
Rats received 50 mg/kg orally for 10 days; body-surface scaling gives roughly 8 mg/kg in humans
Time to effect
Recovery after poisoning
Day 3–7
Benefits appeared from day 3–7 of treatment
Functional normalization after poisoning
By day 10
Versus day 16 in controls
Endurance in healthy volunteers
Within a single 6-hour workload
Improved endurance and recovery during 6- and 24-hour workloads

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • People under 18 years
  • People with bleeding disorders, or within 7 days before or after surgery
  • People with low blood pressure (systolic below 90 mmHg)
  • People with recurrent hypoglycemia or insulin-treated diabetes
  • People with moderate or severe liver impairment (Child-Pugh Class B or C)
  • People with severe kidney impairment (eGFR below 30 mL/min/1.73 m²)
  • Competitive athletes subject to anti-doping testing
  • People taking barbiturates (phenobarbital, butalbital)
    •
Key Interactions
  • Blood pressure drugs and calcium-channel blockers (amlodipine, verapamil, diltiazem): Caution. Possible additive blood pressure lowering.
  • Anticoagulants (clot-slowing drugs: warfarin, apixaban) and antiplatelet drugs (clopidogrel): Caution. Possible added bleeding.
  • Glucose-lowering drugs (insulin, glipizide, glibenclamide): Caution. Class concern for hypoglycemia.
  • Narrow-margin drugs (digoxin, lithium, phenytoin): Monitor. Blood levels may shift.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: aspirin, ibuprofen, naproxen): Caution. Additive platelet inhibition.
  • Antiplatelet supplements (fish oil, Ginkgo biloba, high-dose vitamin E, garlic extract): Caution. Additive bleeding tendency.
  • Blood-pressure-lowering supplements (magnesium, beetroot nitrate, hawthorn): Monitor. Additive lowering of blood pressure.
  • Other actoprotectors and antihypoxants (bemitil, bromantane, Mexidol, Hypoxen): Avoid stacking.
  • Alcohol: Caution. Added liver burden.
  • High-altitude exposure or hypoxic training: Monitor. Could alter oxygen loading in the lungs at altitude.
    •

Risk & Side Effects

  • High: Injection-site reactions
    •
  • Medium:
  • Low: Class effects shared with bemitil; drug accumulation with impaired liver or kidney function
    •
  • Speculative: Blood pressure lowering; bleeding tendency; low blood sugar; unknown long-term toxicity
    •

Monitoring

Marker Target Why
ALT 10–25 U/L Liver-cell injury
AST 10–25 U/L Liver and muscle injury
Total bilirubin 0.3–1.0 mg/dL Liver processing capacity
Creatinine with eGFR eGFR above 90 mL/min/1.73 m² Kidney clearance of the drug
Fasting glucose 75–90 mg/dL Detects low or unstable blood sugar
Platelet count 150–350 ×10⁹/L Baseline clotting-cell supply
Blood pressure Below 120/80 mmHg, systolic above 100 Detects additive lowering

Cadence: Baseline panel before any course; home blood pressure and fasting glucose daily on days 1–3; repeat liver and kidney panels at the end of each 7–10 day course; full baseline panel repeated before any further course, spaced at least 4–6 weeks apart

Qualitative Assessment

  • Sleep duration and quality compared with the pre-course baseline
  • Perceived exertion and recovery speed after a standardized workout
  • Injection-site pain, redness or hardening, if any injectable form is used
  • Nausea, stomach discomfort or headache
  • Mood, irritability and mental clarity
  • Unusual bruising, nosebleeds or bleeding gums
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.